title: Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.
abstract: OBJECTIVE
  Iodine-131 radiolabeled chimeric tumor necrosis therapy monoclonal antibody ((131)I-TNT) has been approved for the treatment of advanced lung cancer in China. In the present study, the immunogenicity of TNT was studied in advanced lung cancer patients using BIACORE and enzyme linked immunosorbent assay (ELISA) methods.
  
  
  METHODS
  Serum samples from 78 advanced lung cancer patients were analyzed for antibody development to TNT after systemic or intratumoral administration of two doses of (131)I-TNT. Patients' sera were obtained before, and 2 weeks and 2 months after (131)I-TNT radioimmunotherapy.
  
  
  RESULTS
  Four of 78 lung cancer patients (4/78 or 5.13%) developed antibodies to TNT as measured by ELISA method, and 7 of 78 patients (8.97%) development anti-TNT antibody as measured by BIACORE biosensor after 2 doses of (131)I-TNT administration (P > 0.05). All the 4 ELISA-positive patients were also BIACORE-positive. Among the 7 BIACORE-positive patients, 5 (of 42, 11.9%) patients receiving intravenous TNT injection developed antibodies to TNT, and 2 (of 36, 5.56%) patients, receiving intratumoral therapy developed antibodies to TNT. The route of administration of the radiolabeled TNT antibody was not a statistically significant factor in the incidence of anti-TNT antibody. Detailed BIACORE serological analysis showed that the induced antibodies were mostly of the IgG1 subclass.
  
  
  CONCLUSIONS
  (131)I-TNT was immunogenic in only a small minority of advanced lung cancer patients (8.97%). The route of administration did not statistically influence the incidence of anti-TNT antibody after TNT radioimmunotherapy in lung cancer patients.
authors.affiliation: Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing 100071, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Chuanping
authors.initials: C
authors.lastname: Cao
authors.forename: Beilei
authors.initials: B
authors.lastname: Li
authors.forename: Shaoliang
authors.initials: S
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Yin
authors.forename: Jing
authors.initials: J
authors.lastname: Shi
authors.forename: Dan
authors.initials: D
authors.lastname: Ye
authors.forename: Qun
authors.initials: Q
authors.lastname: Tao
authors.forename: Peisheng
authors.initials: P
authors.lastname: Hu
authors.forename: Alan
authors.initials: A
authors.lastname: Epstein
authors.forename: Dianwen
authors.initials: D
authors.lastname: Ju
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000276:immunology*; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy; D020349:Surface Plasmon Resonance
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes